May 20 (Reuters) - Antisense Therapeutics Ltd ANP.AX :
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON RESULTS OF PHASE II CLINICAL TRIAL OF ATL1102 IN DUCHENNE MUSCULAR DYSTROPHY
May 20 (Reuters) - Antisense Therapeutics Ltd ANP.AX :
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON RESULTS OF PHASE II CLINICAL TRIAL OF ATL1102 IN DUCHENNE MUSCULAR DYSTROPHY